Lord, Abbett & Co
KRYS icon

Lord, Abbett & Co’s Krystal Biotech KRYS Stock Holding History

Lord, Abbett & Co’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-151,225
Closed -$27.3M – 552
2025
Q1 		$27.3M Sell
151,225
-64,403
-30% -$10.8M 0.1% 237
2024
Q4 		$33.8M Sell
215,628
-68,531
-24% -$12.2M 0.11% 234
2024
Q3 		$51.7M Sell
284,159
-108,079
-28% -$20.8M 0.16% 173
2024
Q2 		$72M Sell
392,238
-99,994
-20% -$16.8M 0.24% 116
2024
Q1 		$87.6M Sell
492,232
-126,226
-20% -$17.5M 0.28% 107
2023
Q4 		$76.7M Sell
618,458
-52,853
-8% -$5.86M 0.27% 108
2023
Q3 		$77.9M Sell
671,311
-171,337
-20% -$20.9M 0.29% 98
2023
Q2 		$98.9M Sell
842,648
-118,594
-12% -$12.1M 0.34% 84
2023
Q1 		$77M Sell
961,242
-316,780
-25% -$24.9M 0.28% 107
2022
Q4 		$101M Buy
1,278,022
+66,081
+5% +$4.9M 0.36% 76
2022
Q3 		$84.5M Buy
1,211,941
+94,375
+8% +$6.82M 0.31% 89
2022
Q2 		$73.4M Sell
1,117,566
-61,247
-5% -$3.81M 0.26% 110
2022
Q1 		$78.4M Buy
1,178,813
+4,950
+0.4% +$309K 0.21% 137
2021
Q4 		$82.1M Buy
1,173,863
+106,705
+10% +$6.21M 0.19% 169
2021
Q3 		$55.7M Sell
1,067,158
-124,422
-10% -$7.37M 0.13% 235
2021
Q2 		$81M Sell
1,191,580
-194,063
-14% -$13.5M 0.2% 157
2021
Q1 		$107M Buy
1,385,643
+1,271,267
+1,111% +$92.4M 0.27% 104
2020
Q4 		$6.86M Sell
114,376
-2,987
-3% -$149K 0.02% 580
2020
Q3 		$5.05M Sell
117,363
-24,297
-17% -$1.06M 0.02% 565
2020
Q2 		$5.87M Sell
141,660
-74,932
-35% -$3.6M 0.02% 556
2020
Q1 		$9.37M Buy
216,592
+53,851
+33% +$2.82M 0.04% 448
2019
Q4 		$9.01M Sell
162,741
-55,009
-25% -$2.7M 0.03% 539
2019
Q3 		$7.56M Buy
+217,750
New +$9.73M 0.03% 581

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Lord, Abbett & Co's KRYS Position: Q2 2025 in Review

Lord, Abbett & Co sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 151,225 shares — an estimated $27.3M sold.

Lord, Abbett & Co first reported a position in KRYS in Q3 2019 and held it in 23 quarters. The position peaked at $107M in Q1 2021. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Lord, Abbett & Co reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 151,225 Krystal Biotech shares in Q2 2025, an estimated $27.3M.
  • Lord, Abbett & Co first reported a position in Krystal Biotech in Q3 2019 and held it in 23 quarters.
  • Lord, Abbett & Co's Krystal Biotech position peaked at $107M in Q1 2021.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Lord, Abbett & Co's 13F filing for Q2 2025, filed 14 Aug 2025.